Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 1990 Jan;45(1):3–8. doi: 10.1136/thx.45.1.3

Immunosuppression by pulmonary surfactant: mechanisms of action.

M L Wilsher 1, D J Parker 1, P L Haslam 1
PMCID: PMC475629  PMID: 2321174

Abstract

Pulmonary surfactant has been shown by this group to suppress peripheral blood lymphocyte responses to mitogens and alloantigens in a dose dependent manner, though the mechanism of action of the suppressive effect is not clearly understood. To try to clarify this, attempts were made to reverse the effects of preincubation with surfactant, obtained by bronchoalveolar lavage from pigs, on lymphocytes and accessory monocytes obtained from the blood of normal volunteers, by washing and incubating the cells in medium alone for various periods up to 24 hours. Immunosuppression, measured as the reduction in thymidine incorporation in response to the mitogen phytohaemagglutinin, could not be reversed by these methods. The addition of indomethacin (up to 100 micrograms/ml for 72 hours) also had no effect, indicating that the immunosuppression was not related to synthesis of prostaglandins. Incubation with surfactant for as little as two hours before addition of mitogen suppressed in vitro lymphoproliferative responses by half, but surfactant added two hours after mitogen had no observed effect. Preincubation of purified lymphocytes in surfactant, before they were cultured with accessory monocytes and mitogen, caused significant suppression of response, but preincubation of purified monocytes had no suppressive effect. There was no change in the intensity of HLA-DR expression on monocytes. These results support the hypothesis that surfactant exerts its effects on the resting uncommitted lymphocyte rather than on antigen presenting monocytes.

Full text

PDF
3

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andrieu J. M., Eme D., Venet A., Audroin C., Tourani J. M., Stern M., Israel-Biet D., Beldjord K., Driss F., Even P. Serum HIV antigen and anti-P24-antibodies in 200 HIV seropositive patients: correlation with CD4 and CD8 lymphocyte subsets. Clin Exp Immunol. 1988 Jul;73(1):1–5. [PMC free article] [PubMed] [Google Scholar]
  2. Ansfield M. J., Kaltreider H. B., Benson B. J., Caldwell J. L. Immunosuppressive activity of canine pulmonary surface active material. J Immunol. 1979 Mar;122(3):1062–1066. [PubMed] [Google Scholar]
  3. Curtiss L. K., Edgington T. S. Effect of LDL-In, a normal immunoregulatory human serum low density lipoprotein, on the interaction of macrophages with lymphocytes proliferating in response to mitogen and allogeneic stimulation. J Immunol. 1977 Jun;118(6):1966–1970. [PubMed] [Google Scholar]
  4. Davis L., Lipsky P. E. Signals involved in T cell activation. II. Distinct roles of intact accessory cells, phorbol esters, and interleukin 1 in activation and cell cycle progression of resting T lymphocytes. J Immunol. 1986 May 15;136(10):3588–3596. [PubMed] [Google Scholar]
  5. Demenkoff J. H., Ansfield M. J., Kaltreider H. B., Adam E. Alveolar macrophage suppression of canine bronchoalveolar lymphocytes: the role of prostaglandin E2 in the inhibition of mitogen-responses. J Immunol. 1980 Mar;124(3):1365–1370. [PubMed] [Google Scholar]
  6. Ettensohn D. B., Roberts N. J., Jr Human alveolar macrophage support of lymphocyte responses to mitogens and antigens. Analysis and comparison with autologous peripheral-blood-derived monocytes and macrophages. Am Rev Respir Dis. 1983 Sep;128(3):516–522. doi: 10.1164/arrd.1983.128.3.516. [DOI] [PubMed] [Google Scholar]
  7. Hughes D. A., Haslam P. L. Changes in phosphatidylglycerol in bronchoalveolar lavage fluids from patients with cryptogenic fibrosing alveolitis. Chest. 1989 Jan;95(1):82–89. doi: 10.1378/chest.95.1.82. [DOI] [PubMed] [Google Scholar]
  8. Hünig T. The role of accessory cells in polyclonal T cell activation II. Induction of interleukin 2 responsiveness requires cell-cell contact. Eur J Immunol. 1983 Jul;13(7):596–601. doi: 10.1002/eji.1830130716. [DOI] [PubMed] [Google Scholar]
  9. Jobe A., Ikegami M. Surfactant for the treatment of respiratory distress syndrome. Am Rev Respir Dis. 1987 Nov;136(5):1256–1275. doi: 10.1164/ajrccm/136.5.1256. [DOI] [PubMed] [Google Scholar]
  10. Kelly J. P., Johnson M. C., Parker C. W. Effect of inhibitors of arachidonic acid metabolism on mitogenesis in human lymphocytes: possible role of thromboxanes and products of the lipoxygenase pathway. J Immunol. 1979 Apr;122(4):1563–1571. [PubMed] [Google Scholar]
  11. Lipscomb M. F., Lyons C. R., Nunez G., Ball E. J., Stastny P., Vial W., Lem V., Weissler J., Miller L. M. Human alveolar macrophages: HLA-DR-positive macrophages that are poor stimulators of a primary mixed leukocyte reaction. J Immunol. 1986 Jan;136(2):497–504. [PubMed] [Google Scholar]
  12. Morley C. J., Banhham A. D., Johnson P., Thorburn G. D., Jenkin G. Physical and physiological properties of dry lung surfactant. Nature. 1978 Jan 12;271(5641):162–163. doi: 10.1038/271162a0. [DOI] [PubMed] [Google Scholar]
  13. Morse J. H., Witte L. D., Goodman D. S. Inhibition of lymphocyte proliferation stimulated by lectins and allogeneic cells by normal plasma lipoproteins. J Exp Med. 1977 Dec 1;146(6):1791–1803. doi: 10.1084/jem.146.6.1791. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. O'Neill S., Lesperance E., Klass D. J. Rat lung lavage surfactant enhances bacterial phagocytosis and intracellular killing by alveolar macrophages. Am Rev Respir Dis. 1984 Aug;130(2):225–230. doi: 10.1164/arrd.1984.130.2.225. [DOI] [PubMed] [Google Scholar]
  15. Rich E. A., Tweardy D. J., Fujiwara H., Ellner J. J. Spectrum of immunoregulatory functions and properties of human alveolar macrophages. Am Rev Respir Dis. 1987 Aug;136(2):258–265. doi: 10.1164/ajrccm/136.2.258. [DOI] [PubMed] [Google Scholar]
  16. Rivnay B., Globerson A., Shinitzky M. Peturbation of lymphocyte response to concanavalin A by exogenous cholesterol and lecithin. Eur J Immunol. 1978 Mar;8(3):185–189. doi: 10.1002/eji.1830080309. [DOI] [PubMed] [Google Scholar]
  17. Shine T. E., Little J. R., Shore V., Medoff G., Abegg A. Effect of exogenous lipids and lipoproteins on the primary immune response in vitro. Eur J Immunol. 1980 Sep;10(9):714–718. doi: 10.1002/eji.1830100911. [DOI] [PubMed] [Google Scholar]
  18. Shinitzky M., Inbar M. Difference in microviscosity induced by different cholesterol levels in the surface membrane lipid layer of normal lymphocytes and malignant lymphoma cells. J Mol Biol. 1974 Jan 5;85(4):603–615. doi: 10.1016/0022-2836(74)90318-0. [DOI] [PubMed] [Google Scholar]
  19. Singer S. J., Nicolson G. L. The fluid mosaic model of the structure of cell membranes. Science. 1972 Feb 18;175(4023):720–731. doi: 10.1126/science.175.4023.720. [DOI] [PubMed] [Google Scholar]
  20. Sitrin R. G., Ansfield M. J., Kaltreider H. B. The effect of pulmonary surface-active material on the generation and expression of murine B- and T-lymphocyte effector functions in vitro. Exp Lung Res. 1985;9(1-2):85–97. doi: 10.3109/01902148509061530. [DOI] [PubMed] [Google Scholar]
  21. Stubbs C. D., Smith A. D. The modification of mammalian membrane polyunsaturated fatty acid composition in relation to membrane fluidity and function. Biochim Biophys Acta. 1984 Jan 27;779(1):89–137. doi: 10.1016/0304-4157(84)90005-4. [DOI] [PubMed] [Google Scholar]
  22. Wilsher M. L., Hughes D. A., Haslam P. L. Immunomodulatory effects of pulmonary surfactant on natural killer cell and antibody-dependent cytotoxicity. Clin Exp Immunol. 1988 Dec;74(3):465–470. [PMC free article] [PubMed] [Google Scholar]
  23. Wilsher M. L., Hughes D. A., Haslam P. L. Immunoregulatory properties of pulmonary surfactant: effect of lung lining fluid on proliferation of human blood lymphocytes. Thorax. 1988 May;43(5):354–359. doi: 10.1136/thx.43.5.354. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES